Doximity, Inc. (DOCS)
AI stock analysis · as of Aug 10, 2026
Loading microstructure…
Doximity operates a dominant U.S. physician social/workflow network (85%+ of doctors) monetized primarily through pharma marketing subscriptions, with an emerging Clinical AI Suite (Scribe, Ask, Dialer) as a second growth leg. Financially, it is a rare software profile: ~88% gross margins, ~30% net margins, $317M FCF, and effectively no debt. The core investment question is whether the AI narrative and pharma ad reacceleration justify paying a premium for a business now growing revenue only ~7-13% YoY, against a backdrop of 7 downgrades in 90 days and shares down ~24% and 64% off 52-week highs.
valuationFair-to-slightly-cheap on cash flow (4.9% FCF yield, EV/EBITDA 20.2x, forward P/E 17.6x, PEG 0.59) for an 88% gross margin business, but the 7% revenue growth print makes it hard to argue outright cheap until AI-driven reacceleration is proven.
This analysis is from Aug 10, 2026. Want the latest on DOCS, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Elite unit economics: 88% gross margin, 21.5% operating margin, 25.5% net margin, and $317M FCF on $645M revenue (~49% FCF margin) — best-in-class SaaS profile
- · Fortress balance sheet: $219M cash vs. only $10M debt, buyback authorizations in May 2024 and Feb 2026 provide EPS support and downside cushion
- · Clinical AI Suite traction: 140+ health systems already adopted, and CEO claims outperformance vs. Anthropic models — a credible enterprise upsell path beyond pharma
- · PEG of 0.59 and forward P/E of 17.6 look reasonable if AI-driven reacceleration materializes; Q1 FY2027 delivered a revenue beat and raised full-year guide
- · Elevated short interest (16.1% of float, 5.99 days to cover) sets up squeeze potential on any positive Nov 5 print
- · 97% institutional ownership signals deep professional conviction despite the drawdown
Bear case
- · Growth deceleration: revenue growth just 7.3% (TTM key metrics) to ~13% (FY26 reported), and earnings growth -51.9% YoY as AI investment costs pressure EPS
- · Consensus deteriorating hard: 7 analyst downgrades vs. 0 upgrades in 90 days, latest from B of A Securities on 2026-06-29 — the sell-side is losing conviction
- · Customer concentration risk explicitly flagged in the 10-K (Customer B material to FY26 revenue); pharma ad budgets are cyclical and subject to patent cliffs
- · AI competitive pressure from OpenAI, Anthropic, Abridge, OpenEvidence, Google, and Microsoft threatens to commoditize the very Clinical AI Suite the bull case rests on
- · Prior goodwill impairment (Q2 FY25) and FY24 restructuring suggest management has misjudged growth investments before
- · Dual-class structure concentrates voting with insiders, limiting shareholder recourse; stock still trades ~64% below 52-week high of $76.51 suggesting sentiment remains fragile
Catalysts
- · Nov 5, 2026 earnings — key test of AI-driven guidance raise and pharma subscription momentum
- · Short squeeze potential on a beat given 16.1% short float and 5.99 days to cover
- · Enterprise Clinical AI Suite contract announcements beyond the current 140+ health systems
- · Buyback execution under the Feb 2026 authorization supporting EPS/share count
- · Pathway Medical (July 2025 acquisition) integration milestones and product roadmap deliverables
- · Any analyst upgrade reversing the 7-0 downgrade skew would shift sentiment materially
Key risks
- · AI commoditization eroding pricing power on Scribe/Ask/Dialer before enterprise revenue scales
- · Pharma marketing budget contraction tied to macro or patent-cliff dynamics hitting the core subscription business
- · Continued analyst downgrades and negative EPS revisions compressing the multiple further
- · HIPAA/PHI breach event triggering regulatory action and enterprise indemnification claims
- · Loss or renegotiation of Customer B or other top pharma accounts
What to watch
- · Nov 5, 2026 earnings — revenue growth trajectory, updated FY27 guide, and AI Suite contribution disclosure
- · Change in analyst upgrade/downgrade skew from the current 7-0 negative posture
- · Short interest trend — currently 16.1% of float, 5.99 days to cover
- · $27 spot vs. 52-week low of $17.15 (key support) and $76.51 high; watch $30-32 resistance
- · Any disclosed enterprise AI contract wins or Pathway Medical integration progress
- · Buyback pace under the Feb 2026 authorization
Key metrics
Price target rationale
Base $31 = ~20x forward EPS on modest AI-driven reacceleration, roughly in line with consensus. Bull $44 assumes Clinical AI Suite drives revenue growth back to 20%+ and multiple re-rates to 28x forward EPS on squeeze dynamics. Bear $19 reflects further growth deceleration, continued downgrades, and multiple compression to ~13x forward EPS near 52-week low.
On Wall Street's view (mixed): The $29.41 consensus target sits just 7% above spot and is credible given the 7-0 downgrade skew, but it likely understates upside if the Nov 5 print confirms AI-driven reacceleration; the wide $18-$47 range reflects genuine disagreement we share.
Latest filing (10-K)
Doximity is a near-monopoly physician network monetizing 85%+ U.S. doctor reach through pharma ad subscriptions and a fast-growing Clinical AI Suite, generating high margins with no debt and a $9.9B market cap, but faces rising AI competition and pharma budget cyclicality.
Doximity is the largest professional network for U.S. physicians, with over 3 million registered members representing more than 85% of U.S. physicians. The platform is free for medical professionals and monetized through subscription-based Marketing Solutions (sponsored content to pharma and health systems), Hiring Solutions (digital recruiting for health systems and staffing firms), and Workflow Solutions (telehealth, AI documentation, scheduling, and clinical AI tools sold to enterprises). Revenue is predominantly subscription-based, with pharmaceutical manufacturers and health systems as the primary paying customers.
What the news says · bullish
Doximity's Q1 FY2027 earnings triggered an extraordinary single-day surge of roughly 38-100% (headlines vary, likely reflecting intraday vs. close moves), driven primarily by a revenue beat, a raised full-year forecast, and CEO commentary that the company's clinical AI outperformed Anthropic's models. Despite an earnings-per-share miss attributed to higher AI investment costs, the market clearly rewarded the forward guidance and AI narrative. Analyst price targets were lifted broadly, and institutional buying was noted post-earnings. The one cautionary note is that even after the surge, at least one outlet flags the stock remains ~32% below its AI-powered peak, and analyst views on AI growth sustainability are split, suggesting some valuation debate remains.
This analysis is from Aug 10, 2026. Markets move. Get the current read on DOCS and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.